Five notes:
1. The spinal biologics market is estimated at $1.9 billion for 2020, with the U.S. accounting for $504 million.
2. The revised report reduced previously communicated projections due to the economic implications caused by the COVID-19 pandemic.
3. The bone graft market segment is expected to rise at a CAGR of 2.6 percent and reach $1.4 billion by 2027.
4. China is anticipated to see a 5.2 percent CAGR in the spinal biologics market, hitting $457.7 million by the end of the forecast period.
5. Japan, Canada and Germany are highlighted as noteworthy market competitors.
More articles on biologics:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don’t
Stryker’s ASC-focused business: 3 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
